Background {#Sec1}
==========

Identified in the 1950's \[[@CR1]--[@CR3]\], Zika virus (ZIKV) emerged as a critical public health issue only in 2015, when it caused a large epidemic in Latin America and the Caribbean that brought previously overlooked complications to light \[[@CR4]--[@CR8]\]. Clusters of microcephaly and neurological manifestations observed in late 2015, together with recognized widespread ZIKV activity in Brazil \[[@CR9]--[@CR12]\], prompted the World Health Organization (WHO) to declare a Public Health Emergency of International Concern from the 1st February until the 18th November 2016 \[[@CR13]\]. Despite the numerous scientific publications on ZIKV infection produced in the past years, crucial information on the natural history as well as on the definition and precise risk quantification of congenital Zika syndrome (CZS) and other developmental abnormalities are still lacking, and well characterized prospective cohort studies are needed to clarify these.

Here we report the design of the prospective multicentre observational cohort studies conducted within the European Commission (EC) Horizon 2020 (H2020)-funded ZIKAlliance Consortium (<https://zikalliance.tghn.org/>). The Consortium as a whole includes 53 partners and is organized in eight scientific and one management work packages (WPs), as well as three cross-cutting WPs, which have been added to organize collaboration with the other EC H2020-funded consortia: ZikaPlan (<https://zikaplan.tghn.org>) and ZikAction ([http://zikaction.org/](http://zikaction.org/))). The cross-cutting WPs relate to the harmonization of protocols and data sharing, to common management and communication strategy, and to the organization of a joint preparedness network in Latin America and the Caribbean. In this manuscript, we focus on the design of the clinical observational studies comprising the "Clinical Sciences" (WP1) and "Clinical Biology and Immunology" (WP2) WPs. These include a Pregnant Women (PW) cohort, a Children (CH) cohort, a Natural History (NH) cohort, and a number of connected substudies (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1ZIKAlliance clinical cohorts: Pregnant Women (PW) cohort, Children (CH) cohort, and Natural History (NH) cohorts, including connected substudies and decentralized biobank

With this integrated prospective research approach, we aim to i) quantify the risk of complications in CH born to mothers infected during pregnancy, ii) identify risk factors for these complications, and iii) describe the NH of infection, disease and development in these CH as well as iv) in adults. Clinical sites have been selected over a wide geographic region bearing in mind the evolving course of the ZIKV epidemic, allowing flexibility in enrolment by shifting towards areas with new or ongoing ZIKV transmission. The network of clinical sites builds on pre-existing networks for dengue virus (DENV) studies \[[@CR14]\], with the goal to expand to a broad platform of collaborations and institutional partnerships between Europe, Latin America and the Caribbean dedicated to emerging diseases preparedness research. Here, we describe the main study designs and the common diagnostic and biobanking approach.

Methods {#Sec2}
=======

Study sites {#Sec3}
-----------

The PW and CH cohort studies are carried out in selected study sites across Latin America and the Caribbean (Fig. [2](#Fig2){ref-type="fig"}). Study sites are selected based on a) existing or recent ZIKV transmission, combined with ongoing collaborative research (for example the EC-funded IDAMS-Dengue study \[[@CR14]\]); and b) on the projection of the fringes of the mosquito vectors distribution \[[@CR15]\]. The latter is aimed at including locations still vulnerable for future outbreaks of ZIKV in Latin America at the time of the start of the study in 2016/17. Wherever available, community seroprevalence surveys are used to target regions where ongoing transmission is likely \[[@CR16]--[@CR18]\]. Fig. 2ZIKAlliance study sites for the pregnant women (PW), and children (CH) cohorts (map showing environmental suitability of Zika virus transmission according to Messina et al., 2016 \[[@CR15]\], modified with inclusion of ZIKAlliance study sites) Fig. 3ZIKV birth cohort comprising pregnant women (PW) and children (CH) cohort studies

Pregnant women (PW) cohort study {#Sec4}
--------------------------------

Strong evidence has been produced for a causal relationship between ZIKV infection during pregnancy and microcephaly of the baby (as well as a range of other congenital anomalies) through clinical-epidemiologic studies \[[@CR8], [@CR19]--[@CR21]\], histopathological and virologic demonstration of ZIKV in affected tissues \[[@CR22]--[@CR24]\], and supportive evidence from in vitro studies and animal infection models \[[@CR25]--[@CR28]\]. However, the quantification of this relationship has proven difficult to measure. Co-factors or effect modifiers have been suggested to be of importance \[[@CR29]--[@CR31]\], but their exact role has not been adequately measured.

We aim to estimate the absolute and relative risk of ZIKV-associated congenital abnormalities and evaluate the role of co-factors or effect modifiers responsible for the variability of the risk currently observed across Latin America and the Caribbean, including previous exposure to other arboviruses. This will require strong support from the laboratories linked to the enrolling sites, in order to develop the expertise and tools needed to diagnose and monitor maternal, foetal and neonatal infections with high sensitivity and specificity.

**Box 1** Key Information of the ZIKAlliance Pregnant Women (PW) cohort study **Pregnant Women (PW) cohort (**[**clinicaltrials.gov**](http://clinicaltrials.gov) **identifier: NCT03188731)Primary Objectives**1. To estimate the absolute and relative risks of congenital abnormalities and adverse pregnancy outcomes associated with Zika virus (ZIKV) infection during pregnancy2. To describe the spectrum of abnormalities and adverse pregnancy outcomes associated with ZIKV infection during pregnancy, further characterizing the congenital Zika syndrome (CZS)**Secondary Objectives**1. To improve the diagnosis of ZIKV infection in PW and neonates2. To measure the incidence and risk factors of ZIKV infection in PW across a number of sites in Latin America and the Caribbean3. To describe the clinical spectrum of ZIKV infection during pregnancy, and determine the proportion of symptomatic and asymptomatic infections4. To determine the rate and risk factors of mother-to-child transmission of ZIKV (cross-cutting objective with the children \[CH\] cohort \[see below\])5. To evaluate the role of co-factors or effect modifiers affecting the variability of current risk estimates for congenital abnormalities6. To compare the risk of infant abnormalities and other adverse outcomes between symptomatic and asymptomatic PW7. To measure the association between time of ZIKV infection during pregnancy and resulting abnormalities in the foetus or other pregnancy outcomes**Inclusion/exclusion**Inclusion criteria• Age ≥ 16 years old• Confirmed pregnancy• Gestational age ≤ 27 weeks (extended to ≤32 weeks for inclusion in the first month of transmission at a location with marked transmission)• Available and willing to undergo study visits and procedures• Written informed consent (assent form and consent by a legal guardian if applicable)Exclusion criteria• Participation in another PW cohort study concerning ZIKV**Endpoints**• Congenital abnormality or adverse pregnancy outcome (according to the evolving definition of the CZS)

### Study design {#Sec5}

Screening of PW will take place in routine antenatal care clinics in selected sites in Latin America and the Caribbean. PW will be enrolled regardless of ZIKV symptoms at baseline.

PW will be followed over the course of the pregnancy approximately every 4 weeks making use of routine antenatal care visits and revisited at delivery (or after miscarriage/abortion) with assessment of rash/fever illness episodes and collection of serial blood/urine samples. Investigations will also include a comprehensive assessment of potential co-factors or effect modifiers for the risk of congenital malformations in ZIKV-infected PW, such as demographics, socio-economic status, living conditions, TORCHS infections (Toxoplasmosis, Rubella, Cytomegalovirus, Herpes and Syphilis; to be tested in a subset and according to national guidelines), HIV serostatus, previous flavivirus infections or vaccines (e.g. DENV or yellow fever \[YF\]), environmental toxins, and chromosomal abnormalities. Symptomatic infections with other arboviruses (including, but not limited to DENV, Chikungunya \[CHIKV\], YF, Mayaro, Oropouche) during pregnancy will also be evaluated as possible co-factors. PW with suspected or confirmed ZIKV infection will be managed according to national protocols.

The visit at birth will be considered the last visit in the PW cohort and the starting point for the CH cohort. Samples from placenta, amniotic fluid, cord blood, maternal blood and urine and blood from the infant will be collected at the birth visit. All newborns will receive a detailed examination. Any abnormalities will be recorded and evaluated according to the evolving definition of the CZS \[[@CR32]\]. Laboratory-confirmed ZIKV infection will be defined based on a positive ZIKV quantitative reverse transcriptase (RT)-PCR in either body fluid or tissue biopsy (e.G. *placenta*). Seroconversion between paired samples collected at different points of time may be considered as a possible recent ZIKV infection. In view of the conflicting evidence on the specificity of currently available serological assays, the final stratification will be based on an exhaustive evaluation of a subset of PW, which will include the use of (combinations of) assays developed to increase discriminatory power for flavivirus antibody testing \[[@CR33], [@CR34]\]. Over the course of this study, both laboratory and clinical diagnostic criteria may undergo modifications based on results from this study and others.

Children (CH) cohort study {#Sec6}
--------------------------

Infants with in utero ZIKV exposure may present with variable degrees of abnormalities, ranging from unapparent infection to a recognizable pattern of structural anomalies and functional disabilities, most of them due to nervous system damage \[[@CR19], [@CR35]--[@CR37]\]. However, a normal examination at birth does not guarantee normal development. Post-natal ocular abnormalities have been reported in infants born with and without microcephaly \[[@CR38], [@CR39]\]. Late-term neurologic and cognitive abnormalities for these infants are considered to be likely, but are largely unknown. Moreover, it is unclear whether perinatal and early post-natal infections could also lead to complications. This is suggested by the description of immune-mediated neurological complications among infants infected postnatally and abnormalities among infants whose mothers were exposed to ZIKV in the third trimester of pregnancy \[[@CR40], [@CR41]\].

We aim to determine the absolute and relative risks of developmental and neurological abnormalities in the first 2 years of life in CH born to women infected with ZIKV during pregnancy.

**Box 2** Key information of the ZIKAlliance Children (CH) cohort study **Children cohort (CH;** [**clinicaltrials.gov**](http://clinicaltrials.gov) **identifier: NCT03393286)Primary Objectives**1. To estimate the absolute and relative risks of developmental, neurological, ophthalmic, and auditory abnormalities during the first 2 years of life in children born to women infected with Zika virus (ZIKV) during pregnancy compared to women not infected during pregnancy2. To describe the spectrum of abnormalities and clinical course during the first 2 years of life in children born to women with ZIKV, dengue virus (DENV) Chikungunya (CHIKV) or possibly other arbovirus infections during pregnancy**Secondary Objectives**1. To evaluate risk factors for developmental abnormalities in children exposed to ZIKV during pregnancy2. To describe the incidence of ZIKV infections after birth in early childhood and evaluate the associated risks for abnormal child development;3. To determine the incidence of ZIKV infection in the mother after birth and evaluate its clinical features as well as its kinetics in different body fluids4. To determine the rate and risk factors and effect modifiers for congenital, perinatal and postnatal mother-to-child transmission of ZIKV5. To describe the kinetics and evolution of infection and immune responses to ZIKV infection in infants and children, stratified by transmission pattern (for example in utero vs. post-natal)**Inclusion/exclusion** (Fig. [3](#Fig3){ref-type="fig"})Inclusion criteria• Group A: Infants born to mothers with confirmed ZIKV infection during pregnancy• Group B: Infants born to mothers with confirmed DENV, CHIKV or other arboviral infection during pregnancy (detected in incident fever/rash episodes)• Group C: Random sample of infants born to mothers without ZIKV/DENV/CHIKV or another arboviral infection during pregnancy (from ZIKAlliance PW cohort), 1:1 proportion compared to groups A and B together. The remaining children from mothers who were not infected with any of the three arboviruses are followed in Group D (standard visitation schedule)• Mother-infant pairs available to undergo study visits and procedures• Written informed consent (assent form and consent by a legal guardian if applicable)Exclusion criteria• Mother aged below 16 years old**Endpoints**• Infant developmental abnormalities as assessed by neurological examination, Ages & Stages Questionnaire® and Bayley Scales of Infant Development

### Study design {#Sec7}

CH of women exposed to ZIKV during pregnancy, and a subset of those not exposed, will be followed after birth for developmental milestones (neuro-cognitive, motor, ophthalmic, and auditory defects) and also to assess the risk of post-natal ZIKV infection among susceptible infants. We will also follow CH of women with incident arboviral infection (including DENV, CHIKV or other such as YF) detected in symptomatic fever/rash episodes over the course of the pregnancy.

At delivery (last visit of PW study), investigations of the mother will include a full blood count, serological tests for ZIKV as well as RT-PCR-testing in blood and urine for ZIKV. The presence of potential environmental pollutants will be tested in a subsample of PW from appropriate biological materials. In addition, placenta and umbilical cord tissue, cord blood, and amniotic fluid will be collected. All biological material will be collected and stored according to detailed SOP. TORCHS and HIV testing will be carried out according to national guidelines and, if not available, may be performed in stored samples for the purposes of the study.

The investigations performed on the infant at birth will include a standard neonatal examination comprised of Apgar scores, anthropometry, reflexes and muscle tone, and collection of blood via heel prick or venepuncture if necessary. Screening tests will be carried out at birth according to national guidelines. Additional investigations, such as cerebral imaging or collection of cerebrospinal fluid, will be carried out only if medically indicated.

Follow-up visits will be scheduled at ages 1--3, 4--6, 12, and 24 months to assess the infant's development using comprehensive neuro-developmental evaluation instruments (Ages & Stages Questionnaire \[ASQ-3\] and Bayley Scales of Infant Development) \[[@CR42], [@CR43]\]. Blood and urine samples from the infant will be collected to test for ZIKV infection (using RT-PCR) or seroconversion. In the mother, we will also test blood and urine samples, with added testing of saliva and breast milk in breastfeeding women who test RT-PCR-positive in urine or blood. CH with any abnormalities detected at birth or during follow-up will be managed according to national protocols.

Natural history (NH) cohort study {#Sec8}
---------------------------------

The ZIKV epidemic in Latin America and the Caribbean occurred in parallel or following a wave of CHIKV and in the context of a high DENV incidence. Given the high frequency of co-circulating arboviruses and their overlapping clinical features, the correct diagnosis of ZIKV infection based on clinical features and antibody testing is challenging, leading to inaccuracies in notifications \[[@CR44]\], and potentially impairing the implementation of effective public health interventions. The current case definition for symptomatic ZIKV infections is broad \[[@CR45]\] and its performance has not been empirically validated. ZIKV infection may frequently be asymptomatic or associated with mild symptoms including low-grade fever, itchy skin rash, conjunctivitis, arthralgia and myalgia starting 3 to 12 days after infection; asymptomatic infection can occur in up to 80% of individuals \[[@CR8], [@CR46]--[@CR49]\]. Neurologic complications including Guillain-Barré syndrome, myelitis and encephalitis \[[@CR6], [@CR11], [@CR12], [@CR50]--[@CR53]\] have been reported following ZIKV infection \[[@CR30], [@CR31]\] in a frequency of around 1 to 5 per 10,000 adults \[[@CR12]\].

Therefore, in the NH study, patients aged 5 years old and older in ZIKV-endemic areas presenting to healthcare units with acute fever/rash illness or any other biological evidence for ongoing ZIKV infection will be enrolled with baseline PCR testing for ZIKV and other co-circulating arboviruses depending on the local epidemiology (including, but not limited to, DENV and CHIKV). They will be followed daily over the acute illness period in order to obtain a detailed description of the clinical features, leading to validated case definitions. In addition, we will include phone interviews over the first year following acute infection, in order to evaluate the incidence of complications.

Nested into the NH study will be substudies focusing on the transmission, viral kinetics and shedding, antibody responses, and long-term disease burden of ZIKV infection. Symptomatic PW from the PW cohort will also contribute to the knowledge base of the NH study.

The aim of the NH cohort study is to generate evidence for a more precise clinical case definition for ZIKV infections in the context of co-circulating arboviral infections like DENV, CHIKV or YF (vaccination) and to better evaluate the full clinical spectrum of ZIKV infections. The enhanced clinical case definition will be evaluated against the current candidate WHO case definition for ZIKV infection \[[@CR54]\].

**Box 3** Key information of the ZIKAllliance Natural History (NH) cohort study **Natural History (NH) cohort (**[**clinicaltrials.gov**](http://clinicaltrials.gov) **identifier: NCT03204409)Primary Objectives**1. To describe the clinical spectrum of disease manifestations among individuals with febrile illness or rash (including medium-term follow-up) and produce a validated case definition of Zika virus (ZIKV) disease**Secondary Objectives (including substudies)**1. To improve the case definition of ZIKV disease2. To establish a precise biological description of the natural course of the infection, with special emphasis on viral kinetics in body fluids (Household and Viral Kinetics substudies)3. To determine the incidence of complications and long-term sequelae, including severe disease presentations, chronic fatigue, ophthalmologic manifestations, depression and other disabilities (Disability Substudy);4. To investigate the socio-economic impact associated with ZIKV infection (Health Economics Substudy)5. To describe the levels of ZIKV exposure in different epidemiological contexts**Inclusion / exclusion**Inclusion criteria• Age ≥ 5 years• Fever (≥37.5 °C) and/or rash for ≤5 days• Available to undergo study visits and procedures• Written informed consent (assent form and consent by a legal guardian if applicable)Exclusion criteria• Localizing features suggesting an alternative diagnosis, e.g. pneumonia, otitis media**Endpoints**• Clinical characterisation (signs/symptoms) and consequences of ZIKV, dengue virus (DENV), Chikungunya (CHIKV) and possibly other arboviral diseases• Occurrence and duration of viral ZIKV shedding in different biologic fluids• Incidence of ZIKV-associated complications and disability• Prevalence, incidence and risk factors of ZIKV among individuals with high or low risk of potential sexual transmission, as well as among household contacts of index patients.

### Study design {#Sec9}

Participant enrolment for the NH study will take place in primary care and emergency units in selected sites. Patients aged ≥5 years old presenting with acute febrile/rash illness in the last 5 days, and without overt signs/symptoms suggesting alternative diagnosis will be invited to participate.

At enrolment, demographic and clinical information will be collected, with detailed assessment of signs/symptoms currently included in the WHO case definition of Zika virus disease \[[@CR54]\], as well as symptoms of infection with other co-circulating arboviruses such as (but not limited to) DENV or CHIKV, and basic haematology and biochemistry assessments. We will also collect early blood samples during the acute phase of illness for PCR testing of the relevant etiological agent (concentrating on the above-mentioned arboviruses). We will strive to detect additional infectious agents and hence improve the characterization of the clinical phenotype of ZIKV infection compared to other pathogens. Participants will be followed daily (including laboratory investigations) for 2--4 days, with an additional visit at 14 days after enrolment to evaluate the clinical phenotype of the acute illness period and obtain a convalescent blood sample for paired testing. This will also allow the documentation of atypical clinical phenotypes or complicated clinical presentations.

Patients will be contacted by phone over the following year to capture persisting complaints or late complications. Medical management will be carried out according to national guidelines. We will analyse the spectrum of clinical manifestations stratified by age, prior flavivirus immune status, and presence of comorbidities.

Substudies {#Sec10}
----------

Substudies of ZIKV viral kinetics, clustering of ZIKV transmission, impact on disability and health economics, the potential role of antibody enhancement, and co-infections will be connected to the NH and PW cohort studies (Fig. [1](#Fig1){ref-type="fig"}). ZIKV transmission occurs mainly through the bite of an infected female *Aedes* mosquito \[[@CR47]\], but transmission through blood transfusion \[[@CR55]--[@CR57]\], sexual intercourse \[[@CR58]--[@CR65]\] and direct contact through intact skin \[[@CR66]\] have also been reported. ZIKV shedding seems to occur in a range of body fluids, most notably in male genital fluids where shedding can be protracted for months \[[@CR64], [@CR67]\]. Some reports also suggest shedding can also be prolonged in PW \[[@CR27], [@CR68], [@CR69]\]. The frequency and duration of ZIKV shedding in different body fluids is unknown, as is the significance of viral shedding for the risk of person-to-person transmission.

### Seroprevalence studies in communities {#Sec11}

Estimates of ZIKV incidence in affected areas are often based on notifications with insufficient laboratory confirmation resulting in misclassifications due to other circulating arboviruses \[[@CR44]\]. Seroprevalence studies in communities representing the epidemiological context of potential participants will be underway to guide the selection and potential relocation of sites for ZIKAlliance cohorts over the course of the study. Populations under investigation include groups representing a range of socioeconomic status, environmental exposure and susceptibility to viral sexual transmission.

### Viral kinetics substudy {#Sec12}

This substudy will enrol adults with PCR-confirmed ZIKV identified in the cohorts in selected sites who consent with a more intense follow-up including genital samples if possible. Scheduled visits occur at days 7, 14, 21 and 28 after inclusion, then months 3, 6 and 12, with additional collection of samples until no ZIKV is detected in any sample. The primary outcome will be the frequency and duration of ZIKV detection in blood and other body fluids (saliva, urine, genital secretions, breast milk) for 12 months following acute ZIKV infection, and secondary outcomes will include potential associations with clinical manifestations and long-term complications or sequelae.

### Household substudy {#Sec13}

Household (HH) contacts of PW or NH participants with confirmed ZIKV infection will be invited to participate in in selected study sites. The main objective is to compare the prevalence of ZIKV infection in well-defined groups, using RT-PCR in blood and urine samples, as well as serological methods. Of special interest is the ratio of the markers of ZIKV infection between sexual partners compared to other HH contacts. In virologically-confirmed patients, we will conduct phylogenetic analysis to establish potential concordance of ZIKV strains within and between HH. HH contacts will be defined as any person aged 5 years and older spending \> 1 week in the same HH within 1 month of the index patient being identified.

### Disability and health economics substudies {#Sec14}

We will describe medium-term complications and disabilities among ZIKV patients following acute infection, and the impact of ZIKV infection on health, quality of life and disability. We will estimate the socio-economic burden of the disease in terms of use of family resources, loss of income and leisure time.

Laboratory support to studies {#Sec15}
-----------------------------

In order to ensure comparability of inclusions across the sites, protocols, facilities, and capacity for virologic and serological testing will be assessed for the laboratories linked to the clinical centres. Initial molecular testing as well as IgM/G serology will be done locally, with proficiency testing provided through the project. For molecular testing, locally available protocols will be used. Laboratories with insufficient performance in the External Quality Assurance (EQA) testing are supported by laboratory partners in the project for troubleshooting and confirmatory testing.

Molecular testing is the gold standard for ZIKV diagnosis and is definitive evidence for infection. Laboratory testing will be carried out using RT-PCR (in plasma/serum, urine, and other body fluids for ZIKV) and serology (serum/plasma). An initial inventory of essential diagnostic capacity of the laboratories associated with clinical sites was performed, based on a previously developed laboratory capacity and capability survey for ZIKV diagnostics \[[@CR70], [@CR71]\]. Standards have been prepared for molecular diagnostic testing \[[@CR72], [@CR73]\]. EQA for molecular detection of ZIKV was carried out at the start of the study, and will be repeated at regular intervals \[[@CR74]\]. Should lack of sensitivity be noted, the site will be contacted, and test algorithms revisited, including changes in assays or protocols. In order to harmonize laboratory procedures, detailed standardized laboratory protocols were developed describing the sampling frame, sample volumes, shipping and storage conditions.

Several serological assays measuring anti-Zika virus IgM and IgG are commercially available. From the beginning of this study, all sites have been using such assays, for which sensitivity and specificity estimates have ranged from 88 to 95% and 30--98%, respectively \[[@CR75]\]. The highest estimates were generated in targeted evaluation studies during the peak outbreak phase, and in regions with a lower background frequency of prior flavivirus exposure. The choice of the assays will be re-evaluated on a continuous basis and may be adapted according to new developments.

At enrolment, all participants of the PW cohort will be tested for IgG (ZIKV, DENV) and IgM (ZIKV) antibodies as well as via RT-PCR (as mentioned). Previous flavivirus infection status as well as vaccinations, if applicable (i.e. against YF or DENV) will be assessed as potential risk factors. In the case that other (arbo) viruses emerge in a certain location, they will be included in the testing panels. Positive PCR results will be repeated for confirmation including RNA extraction, unless both urine and blood are tested positive initially. IgG and IgM will be repeated at birth. Additional tests (e.g. serology) will be carried out either batched or individually, also depending on the laboratory capacities at each location. In the event of confirmed seroconversion at birth, retrospective testing of samples will be carried out for identification of timing of infection during pregnancy. Serologic tests will be performed using the approved, commercial kits and in the designated laboratories in each country. ZIKV IgM will be tested once every trimester of pregnancy as these antibodies may be short-lived. The best frequency for ZIKV IgM testing will still be subject to validation. In a subset of PW residing in an area with documented ZIKV transmission in the previous season with detectable anti-ZIKV IgG at enrolment, we will evaluate the specificity of the IgG assay by confirmatory virus neutralisation (VNT) assays with ZIKV and DENV and other ZIKV specific serological assays, performed in a reference laboratory. Results of the VNT and other assays may trigger adaptations of the follow-up schedule (e.g. for women who are no longer under risk of ZIKV infection).

Routine laboratory facilities in each participating site will be engaged in performing laboratory tests such as full blood count or biochemistry. TORCHS and HIV screening are part of the routine health investigations of PW in many countries. Where this is not available, TORCHS and HIV screening will be performed in samples from all mothers who have experienced adverse pregnancy outcomes or where congenital abnormalities are documented. In addition, a laboratory capacity strengthening program will be done in liaison with other consortia, and with an European network of diagnostic virology laboratories \[[@CR70], [@CR71], [@CR73]\].

**Box 4** Diagnostics used in the ZIKAlliance studies **DiagnosticsDiagnostic approach**The diagnostic approach is subjected to validation over the course of the study. The diagnostic approach includes:- ZIKV RT-PCR in plasma and urine at every visit for PW, CH and NH protocols- ZIKV IgM/IgG at PW enrolment and at birth (and at least one IgM every trimester of pregnancy)- ZIKV IgM/IgG at every visit of the CH cohort (both mother and child) and in paired samples in participants of the NH study- Dengue virus (DENV) IgG at enrolment in a subset (possibly using new platforms and/or VNT for the assessment of past infection status)- RT-PCR for DENV and CHIKV in addition to ZIKV in symptomatic participants**Harmonisation of diagnostics**An EQA for molecular detection of ZIKV was performed at the start of the study and will be repeated at regular intervals to assess the quality of the currently used molecular test systems for ZIKV detection in the ZIKAlliance diagnostic laboratories. This includes:- An inventory of essential diagnostic capacity in the laboratories associated with clinical sites, based on previously developed capacity, and a capability survey for ZIKV diagnostics- Detailed standardized laboratory protocols describing the sampling frame, sample volumes, shipping and storage conditions- Standards have been prepared for molecular diagnostic testing in the laboratories associated with clinical sites in order to assess sensitivity/specificity issuesIf issues in the precision or accuracy of diagnostic tests are noted, the site is contacted for revision of test algorithms, including changes in assays or protocols.

Data management and biobanking {#Sec16}
------------------------------

Participants will be assured that all information generated in this study will remain confidential. All data (including clinical, laboratory and genetic data) will be stored in password-protected databases. Personal identifier information will be linked to stored data or samples only by a protected Master List (pseudonymization). This list will be kept under lock locally and will not be shared outside the study staff at the local partner site. No identifying information will be transferred between sites or to the central database. A governance board including members from all partners has been defined to coordinate the use and potential sharing of data and samples.

Electronic web-based case report forms (CRFs) have been developed using REDCap \[[@CR76]\]. An electronic data entry interface was set up with the option of online data entry using a tablet device. Patient records will be entered as pseudonymized records (by use of a study identification number), not allowing the personal identification of patients. Clinical data and locally performed laboratory results will be entered directly to the electronic database. If initial data collection is performed in paper CRFs, data entry will be performed in a REDCap electronic CRF that mirrors the layout of the paper form.

Privacy and data safety will be ensured by a secured backup server and restricted access, also accommodating different levels of data access for participant identifiable information. Upon entry, data will automatically be validated across the entire patient record to fit the specific protocol requirements (plausibility and range checks). Data queries and source data verification requests will be generated and relayed back to each participating site for correction. A virtual, decentralized biobank will be created with an inventory of which samples will be available and where, how they will be stored, and what (raw) laboratory data will be associated. Samples will be stored locally, and a governing body created to ensure access and respond to requests for samples. The collection and storage of biological specimens will be regulated by SOP that are accessible to all partners.

Data analysis {#Sec17}
-------------

Because of the exploratory nature of the analysis, we did not conduct an exact sample size calculation. However, some power assessments were performed. For our purposes, we only consider microcephaly, because the variability with regard to the frequency of microcephaly is considerably smaller than that of other congenital abnormalities currently included in the CZS definition. Based on estimates of the Latin American Collaborative Study on Congenital Malformations (ECLAMC) \[[@CR77]\], we assume a baseline risk of 0.025% for microcephaly in children born to ZIKV-uninfected mothers. For mothers ZIKV-infected during pregnancy, we assume a probability of microcephaly between 0.25 and 6% (relative risks between 10 and 240) \[[@CR19], [@CR20], [@CR37], [@CR78]--[@CR81]\]. Furthermore, we assume that the probability of a ZIKV infection during pregnancy ranges between 5 and 30%. With a sample size between 5000 and 6000 we can detect, with 80% power and significance level α = 0.05, a relative risk of 20 when the probability of ZIKV infection is 10% or higher, and a relative risk of 30 when this probability is 5% or higher.

### PW study {#Sec18}

Data analysis will be carried out according to a pre-specified statistical analysis plan. The characteristics of the PW included will be assessed in a descriptive analysis, taking into account the grouping of the PW by ZIKV infection status. Possible differences between the infection groups will be detected by appropriate measures of location and corresponding tests (e.g. t-test, chi-square test, Wilcoxon rank-sum test). The primary endpoint will be any congenital abnormality or adverse pregnancy outcome, based on the emerging definition of the CZS \[[@CR32]\]. Any congenital abnormality will be assessed at birth but may be updated if an abnormality only becomes apparent later in the neonatal period. In a first step, the primary endpoint will be analysed by a chi-square test. Next, a generalised mixed model will be fitted which contains predefined basic variables. The model will be investigated and modified by a stepwise back- and forward variable selection of the fixed effects. The region (represented by the local partner site or by a group of sites) will be included as a random effect in the model and will account for the heterogeneity between different regions. Sites may be aggregated based on geographical proximity in case of data sparseness. Interaction effects between two variables will only be included if there is a clinical rationale. We will present odds ratios as results of the generalised mixed model. Throughout the analyses, we will use α = 0.05 as significance level.

### CH study {#Sec19}

The primary endpoint in the CH study will be the detection of any developmental abnormality within 2 years of birth. The children in the study are born to women from the PW study or to mothers with proven ZIKV infection during pregnancy. The two-year follow-up brings up the practical restriction of drop-outs as right censoring. Consequently, the primary endpoint will be analysed with survival analysis techniques. Predefined basic variables on the outcome will be included in a Cox model with region as a random factor. Specific developmental abnormalities, which are only measured at one follow-up visit, will be evaluated by mixed logistic models, containing the respective variables, with region as a random effect as above.

### NH study {#Sec20}

The NH study will be carried out at a subset of the sites including participants who experience acute rash/fever illness, suggesting arboviral aetiology. The sample size will depend on the local epidemiology. The statistical analysis will be largely descriptive and informed by prior studies of arboviral rash and febrile illness \[[@CR14], [@CR82]\]. The prospective nature of the study will be used to describe the trajectory over time of signs and symptoms, and hence further define the case definitions of arbovirus infections, including ZIKV.

Harmonisation, clinical monitoring, ethics, and dissemination {#Sec21}
-------------------------------------------------------------

The multicentre cohort studies were built on standardized common protocols as well as a series of SOP to ensure systematic and homogenous execution of clinical and laboratory study procedures and sampling. Harmonisation of protocols for clinical cohorts as well as diagnostic algorithms has been ongoing between members of the ZIKAlliance consortium and other currently active research programs, funded for example by the EC or by the National Institutes of Health (NIH). The benefit of this is that patients can be enrolled and studied outside of ZIKAlliance with compatible protocols, which were made publicly available \[[@CR83]\], and a pooled dataset may later be analysed for the maximum benefit.

Clinical monitoring is integrated into the programme of work from the outset, ensuring compliance with Good Clinical Practice (GCP) standards. The studies are conducted in accordance with the International Conference on Harmonisation - GCP guidelines. A reciprocal clinical monitoring network was set up between the partners of the Consortium as part of preparedness and capacity building.

The observational studies outlined here are conducted in accordance with the principles of the Declaration of Helsinki, the Nagoya protocol, GCP and relevant local regulations. All procedures employed in the clinical and related laboratory studies comply with local and international legislations regarding research involving human subjects, biobanking, and shipping of specimens. The protocols, amendments, consent and assent forms have been submitted to the relevant Research Ethics Committees at each study site, and to relevant regulatory authorities for written approval.

In the case of a clinical episode suggestive of ZIKV, the national standard of care and visitation schedule will be followed. The study team is in close contact with national authorities and will inform the surveillance teams about trends of confirmed infections per site. Unexpected incidental findings (not related to ZIKV or other arboviral infections) may occasionally be identified in individual patients in the course of the clinical study. The patient and/or parent/guardian will be informed, and with their consent, a referral will be made to an appropriate clinic or health facility for further investigation or longer-term follow-up.

Study results will be fed back to participants through periodic reports, and relevant results will also be communicated to healthcare professionals and health authorities. Scientific dissemination will not make use of professional writers and publications resulting from the study will use prevailing authorship eligibility guidelines \[[@CR84]\]. It will be stated that the EC has no role on study design, data collection, analysis, interpretation of results, manuscript writing or decision to publish resulting reports.

Discussion {#Sec22}
==========

After 2018, ZIKV transmission is projected to be low in the major urban areas of Latin America \[[@CR85]\] until susceptibles have built up after approximately 10 years \[[@CR5]\]. In the meantime, the results of these large cohort studies will provide better risk estimates for birth defects and other developmental abnormalities associated with ZIKV infections including possible co-factors that explain the variability of risk estimates currently seen between the Northeast of Brazil and other countries and regions. The ZIKAlliance Consortium covers a broad geographic region in Latin America and the Caribbean in order to represent the different environmental and demographic conditions that may influence the development and outcome of the ZIKV epidemic. These data will help decision-makers to allocate prevention and health care resources according to severity and impact of the epidemic. In addition, the results will provide a historical baseline for future intervention trials, should a vaccine or therapeutics become available and be tested without a control arm, as has recently been done in Ebola vaccine trials \[[@CR86]\].
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